首页> 外文OA文献 >Crystallization process development and spherical agglomerates for pharmaceutical processing applications
【2h】

Crystallization process development and spherical agglomerates for pharmaceutical processing applications

机译:用于制药加工应用的结晶工艺开发和球形附聚物

摘要

The control of crystallization steps is essential in the production of many materials in the pharmaceutical, materials, and chemical industries. Additionally, due to increasing costs of research and development, reductions in manufacturing costs by moving from batch to continuous manufacturing are necessary to sustain profitability of the pharmaceutical industry. Two different projects were researched to progress towards this goal. The first was the demonstration of a continuous manufacturing platform. The second goal was the development of new crystallization techniques. Two continuous crystallization processes were developed as part of a demonstration unit for continuous manufacturing of Aliskiren hemifumarate. The first process was an anti-solvent crystallization of an intermediate. The second process was a continuous reactive crystallization developed for the final product. The processes were able to crystallize the two compounds with both high yield (>90%) and purity (>99%). Population balance modeling was performed and experimental data were fit to the model to obtain kinetic parameters for crystal growth and nucleation for both systems. The models were used to optimize crystal purity and yield of the products. In addition, this thesis describes two separate projects involving spherical agglomerates. In the first study, acetaminophen was shown to crystallize significantly faster in the presence of spherical agglomerates of lactose than single crystal lactose. An epitaxy study and molecular dynamics simulations showed that the (141̄)/(001) pairing of faces showed coincident lattice matching and favorable energy interaction. Maximizing the number of substrate faces available for interaction increases the chance for a lattice match between the substrate and the crystallizing material which can be useful for controlling and increasing nucleation kinetics. Finally, water-in-oil emulsions were used to make composite spherical agglomerates with two components: a heterosurface, and a target compound that does not typically crystallize as spherical agglomerates on its own. The generated composite agglomerates were relatively monodisperse and were characterized using optical microscopy, scanning electron microscopy, x-ray powder diffraction, and differential scanning calorimetry. This technique could potentially be applied to other hydrophilic compounds, in particular water-soluble pharmaceuticals compounds, in order to change crystal morphology to spherical agglomerates in order to simplify downstream processing.
机译:结晶步骤的控制对于制药,材料和化学工业中许多材料的生产至关重要。另外,由于研究和开发成本的增加,为了维持制药业的盈利能力,必须通过从批量生产转向连续生产来降低制造成本。研究了两个不同的项目以实现这一目标。首先是连续生产平台的演示。第二个目标是开发新的结晶技术。作为连续生产阿利吉仑半富马酸盐的示范装置的一部分,开发了两个连续的结晶工艺。第一个过程是中间体的反溶剂结晶。第二个过程是为最终产品开发的连续反应性结晶。该工艺能够以高收率(> 90%)和纯度(> 99%)结晶两种化合物。进行种群平衡建模,并将实验数据拟合该模型以获得两个系统的晶体生长和成核动力学参数。该模型用于优化晶体纯度和产物产率。另外,本文描述了两个单独的涉及球形附聚物的项目。在第一个研究中,对乙酰氨基酚在乳糖的球形团聚体存在下结晶速度明显快于单晶乳糖。外延研究和分子动力学模拟表明,(141̄)/(001)面的配对显示出一致的晶格匹配和良好的能量相互作用。最大化可用于相互作用的衬底面的数量增加了衬底与结晶材料之间晶格匹配的机会,这可用于控制和增加成核动力学。最后,油包水型乳液用于制备具有两种成分的复合球形团聚物:异质表面和通常不会自行结晶为球形团聚物的目标化合物。产生的复合附聚物相对单一分散,并使用光学显微镜,扫描电子显微镜,x射线粉末衍射和差示扫描量热法进行表征。该技术可以潜在地应用于其他亲水性化合物,特别是水溶性药物化合物,以将晶体形态改变为球形附聚物,从而简化下游加工。

著录项

  • 作者

    Quon Justin (Justin Louie);

  • 作者单位
  • 年度 2013
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号